P141 DIFFERENCES IN RECURRENCE SCORE (RS) RESULTS BETWEEN LUMINAL A AND LUMINAL B BREAST CANCER SUBTYPES

Poster Abstracts I

N. Efrat (Ben-Baruch) S. Rizel, R. Yerushalmi, B. Nisenbaum, A. Gabizon, M. Steiner, D.B. Geffen, E. Evron, N. Liebermann, S. Stemmer Department of Oncology, Kaplan Medical Center, Rehovot Israel; Davidoff Center, Rabin Medical Center affiliated with the Sackler Faculty of Medicine (Tel Aviv University), Petah Tikva Israel; Meir Medical Center, Kfar Saba Israel; Shaare Zedek Medical Center, Jerusalem Israel; Oncology, Carmel Medical Center, Haifa Israel; Soroka University Medical Center, Ben-Gurion University of the Negev, Be’er Sheva Israel; Assaf Harofeh Medical Center, Zerifin Israel; Clalit Health Services, Tel Aviv Israel

Goals: Ki-67 has been suggested as a surrogate marker for luminal A and luminal B ER/PR+ breast cancer. Data support Ki-67 as a prognostic but not as a predictive marker. The Oncotype DX® assay is validated as a prognosticator and as predictor of likelihood of chemotherapy benefit. This study assessed the distribution of RS results in luminal A and B breast cancer as defined by Ki-67.

Methods: A retrospective analysis was performed of all breast cancer patients (pts) who underwent Oncotype DX® testing through Clalit Health Services from 2/2006 to 9/2012 and for whom Ki-67 data was available. Ki-67 ?15%, >15% was used as cut-off for luminal A and B tumors. Mann-Whitney and Chi-squared/Fisher exact tests were used to assess the differences in continuous and categorical parameters, respectively, between the luminal A and B groups.

Results: Out of 4147 pts who underwent Oncotype DX® testing, Ki-67 data was available for 1155 pts, of whom 724 (63%) had luminal A and 431 (37%) had luminal B tumors. In both groups, most pts were node negative (71% vs 75%; P = 0.11). The groups were similar in respect to age (median [range], 62 [28–85] vs 60 [30–84] yrs; P = 0.16) and the proportion of PR negative pts (16% vs 17%; P = 0.42). They differed significantly with respect to the proportion of pts with IDC (79% vs 87%; P = 0.0006) and tumor size (median [range], 1.5 [0.2–6.5] vs 1.8 [0.2–6.0] cm; P < 0.0001). Grade distribution varied significantly between the groups (P < 0.0001): the proportion of pts with grade 1 tumors was higher in the luminal A than in the luminal B group (19% vs 3%), and the proportion of pts with grade 3 tumors was higher in the luminal B than in the luminal A group (35% vs 8%). RS results varied significantly between the luminal A and B groups (median [range], 16 [0–49] vs 22 [0–69], respectively; P < 0.0001). RS distribution also varied significantly (P < 0.0001) between the groups: in the luminal A group, 59%, 33% and 4% of pts had low, intermediate, and high RS results, respectively (4% had no RS results) and in the luminal B group, the respective values were 32%, 42%, and 23% (3% had no RS results).

Conclusion: There is a wide distribution of RS results in pts with luminal A and B tumors as defined by Ki-67, underscoring the utility of Oncotype DX®. Almost a third of pts with luminal B tumors had low RS results indicating minimal if any likelihood of benefit from chemotherapy. The
analysis was supported by Genomic Health Inc. A. Gabizon receives research support from Janssen Pharmaceuticals, and serves in the Board of Directors of Liposome Pharmaceuticals.